Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
K
102940
vs
K
KOSPI 200
Over the past 12 months, Kolon Life Science Inc has underperformed KOSPI 200, delivering a return of -62% compared to KOSPI 200's +58% growth.
Stocks Performance
102940 vs KOSPI 200
Performance Gap
102940 vs KOSPI 200
Performance By Year
102940 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kolon Life Science Inc
Glance View
Kolon Life Science is a South Korean pharmaceutical and biotechnology company that develops, makes, and sells medicines. Its core business is prescription drugs for hospitals and clinics, along with other healthcare products used to treat patients through the medical system. It also invests in drug development, which gives it a mix of commercial products today and longer-term research programs. The company makes money mainly by selling finished medicines to wholesalers, hospitals, and other healthcare providers. In a business like this, revenue comes from product sales rather than subscriptions or advertising, so success depends on having drugs that doctors will prescribe and that medical institutions will buy. Its customers are mostly healthcare professionals and organizations, not individual consumers. What makes Kolon Life Science different is that it sits between traditional drug manufacturing and biotech research. It does not just package generic products; it also works on treatments with more specialized medical uses, which can create higher barriers to entry than ordinary consumer health products. That makes it a company whose value depends on both its commercial drug portfolio and its ability to turn research into approved medicines.